PTIXClinical Trials•businesswire•
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
Sentiment:Positive (75)
Summary
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 21, 2025 by businesswire